Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Shares Outstanding (Diluted Average) (2019 - 2025)

Historic Shares Outstanding (Diluted Average) for Ultragenyx Pharmaceutical (RARE) over the last 7 years, with Q3 2025 value amounting to $99.8 million.

  • Ultragenyx Pharmaceutical's Shares Outstanding (Diluted Average) rose 447.91% to $99.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.8 million, marking a year-over-year increase of 447.91%. This contributed to the annual value of $90.5 million for FY2024, which is 2310.76% up from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's Shares Outstanding (Diluted Average) stood at $99.8 million, which was up 447.91% from $98.5 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Shares Outstanding (Diluted Average) ranged from a high of $99.8 million in Q3 2025 and a low of $67.8 million during Q4 2021
  • Over the past 5 years, Ultragenyx Pharmaceutical's median Shares Outstanding (Diluted Average) value was $71.7 million (recorded in 2023), while the average stood at $79.6 million.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Shares Outstanding (Diluted Average) surged by 122.53% in 2023, and later surged by 3325.15% in 2024.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Shares Outstanding (Diluted Average) stood at $67.8 million in 2021, then rose by 3.13% to $69.9 million in 2022, then rose by 5.19% to $73.5 million in 2023, then rose by 23.11% to $90.5 million in 2024, then grew by 10.2% to $99.8 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $99.8 million in Q3 2025, compared to $98.5 million in Q2 2025 and $96.3 million in Q1 2025.